SCHEMBL23055121

SCHEMBL23055121

CCc1cc(F)ccc1C(CC)c1ccc(F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGBL2 Q5U5Z8 1/20 0.38
HPGD P15428 2/20 0.36
ALDH1A1 P00352 3/20 0.35
BCHE P06276 1/20 0.35
TYR P14679 1/20 0.35
ACHE P22303 1/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
KMT2A Q03164 1/20 0.35
FAAH O00519 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
ALOX12 P18054 1/20 0.35
MAPK1 P28482 1/20 0.35
MTOR P42345 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21911296 0.90 PSEN1 (0.41) AGBL2MEN1KMT2A
SCHEMBL25482219 0.82 DAO (0.41) AGBL2ALDH1A1LMNAMAPTMAPK1
SCHEMBL23055119 0.82 ALDH1A1 (0.40) HPGDALDH1A1LMNATSHRNPSR1
SCHEMBL21831133 0.81 F2RL1 (0.45) AGBL2ALDH1A1LMNAMEN1MAPT
SCHEMBL30910896 0.81 F2RL1 (0.45) AGBL2ALDH1A1LMNAMEN1MAPT
SCHEMBL22048339 0.79 BCHE (0.46) HPGDALDH1A1BCHETYRACHE
SCHEMBL21911291 0.79 LMNA (0.36) AGBL2ALDH1A1LMNAMEN1MAPT
SCHEMBL13126150 0.78 CYP17A1 (0.42) HPGDALDH1A1ACHELMNATSHR
SCHEMBL13863848 0.77 AGBL2 (0.38) AGBL2MAPTPKMF2RL1
SCHEMBL16483392 0.77 KDM4E (0.40) LMNAMAPTPKMMAPK1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584747-B2 Substituted pyridopyrimidinonyl compounds useful as T cell activators SYNGENE INTERNATIONAL LIMITED (IN) 2023-02-21 US disclosed
US-20210061802-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS SYNGENE INTERNATIONAL LIMITED (IN) 2021-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584747-B2 Substituted pyridopyrimidinonyl compounds useful as T cell activators DGKZ, DGKA, DGKG AGBL2 3072/4885HPGD 2867/4885ALDH1A1 4233/4885
US-20210061802-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG AGBL2 3072/4885HPGD 2867/4885ALDH1A1 4233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.